GleamWall
中文EN

ZURA Zura Bio Ltd

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1855644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-43.7%
TTM EPS YoY-70.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-65.4%
ROA-55.2%
ROIC (approx.)-164.3%
Asset turnover—

Leverage & solvency

Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.29x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.24x
Accruals ratio-42.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$19.49M$20.71M$14.75M$10.96M$11.95M$8.70M$10.47M$9.24M
SG&A expense$9.28M$8.62M$10.75M$7.46M$7.57M$9.36M$8.78M$6.49M
Operating income-$28.77M-$29.32M-$25.50M-$18.41M-$19.52M-$18.06M-$19.25M-$15.73M
Pretax income-$27.05M-$26.39M-$24.22M-$17.18M-$18.04M-$15.99M-$17.44M-$13.62M
Income tax-$1.22M-$81,000$0—$0$0$0—
Net income-$25.82M-$26.30M-$24.22M-$17.18M-$18.04M-$15.99M-$17.44M-$13.62M
EBITDA-$28.77M-$29.34M-$25.48M-$18.40M-$19.52M-$18.05M-$19.25M-$15.73M
EPS (basic)-0.20-0.21-0.22—-0.21-0.17-0.19—
EPS (diluted)-0.20-0.21-0.22—-0.21-0.17-0.19—
Weighted avg. shares (diluted)127.71M126.80M112.22M—94.56M94.29M92.96M—
Balance sheet
Cash & equivalents$187.65M$205.13M$225.59M$109.41M$139,017$154,490$170.57M$176,498
Current assets$191.59M$210.50M$227.00M$112.31M$142.29M$156.99M$171.69M$178.74M
PP&E, net$153,000$149,000$125,000$126,000$131,000$122,000$106,000$91,000
Total assets$194.63M$213.40M$228.64M$113.95M$143.94M$157.81M$172.50M$179.53M
Current liabilities$16.97M$16.32M$11.74M$12.41M$25.49M$18.70M$21.09M$19.51M
Total liabilities$16.97M$16.32M$11.74M$12.41M$25.49M$18.70M$21.09M$19.51M
Shareholders' equity$177.66M$197.09M$216.90M$101.54M$108.24M$125.91M$138.20M$146.81M
Shares outstanding96.31M95.42M94.88M73.68M65.02M62.06M68.37M65.30M
Cash flow statement
Operating cash flow-$19,498$18.88M-$18.92M-$22.28M-$15,444-$16.03M-$11.06M-$10.82M
Capital expenditure$36-$12,963$13,000$17,000$32$15,000$49,000$45,000
Free cash flow-$19,534$18.90M-$18.94M-$22.30M-$15,476-$16.05M-$11.11M-$10.87M
Investing cash flow-$36$12,963-$13,000-$17,000-$32-$15,000-$49,000-$45,000
Financing cash flow$2,052-$134.99M$135.12M-$7.32M$3-$34,000$5.18M-$854,000
Depreciation & amortization$20-$15,968$16,000$15,000$14$11,000$9,000$5,000
Stock-based compensation$5.32M$4.46M$5.01M$2.58M$2.38M$3.73M$3.64M$2.82M

Free plan shows the latest 8 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.